Cidara Therapeutics (CDTX) Stock Price, News & Analysis

Company Overview

Cidara Therapeutics, Inc. is a clinical‐stage biotechnology company headquartered in San Diego, California, focused on the discovery, development and commercialization of novel therapies for life‐threatening fungal and viral infections. Founded in 2015, the company leverages its proprietary platforms to develop long‐acting therapeutics designed to address significant unmet medical needs. Cidara’s research and development efforts are centered on creating treatments with improved safety, dosing convenience and broad-spectrum activity.

The company’s lead antifungal candidate, rezafungin (CD101), is a next‐generation echinocandin designed for once‐weekly intravenous or topical administration. Rezafungin is being evaluated for the prevention and treatment of invasive candidiasis, candidemia and other serious fungal infections, with the aim of reducing hospital stays and improving patient outcomes. Cidara has established strategic collaborations and licensing partnerships to support global development and commercialization of rezafungin.

In parallel, Cidara is advancing its Cloudbreak® mRNA platform to generate prophylactic and therapeutic antibodies against viral pathogens, including influenza and coronaviruses. This platform uses modified mRNA to program the human body to produce protective antibodies in vivo, offering potential for rapid response to emerging viral threats. Early‐stage programs include long‐acting antibody products for the prevention of COVID-19 and seasonal flu, positioning Cidara at the forefront of mRNA‐based immunotherapies.

Cidara’s leadership team combines expertise in infectious disease, drug development and regulatory affairs. Under the direction of President and CEO Jeffrey Cleland, Ph.D., the company has advanced its pipeline through multiple clinical milestones and regulatory interactions. Cidara operates primarily in the United States, with partnerships and development activities extending into Europe and Asia. The company continues to expand its scientific collaborations with academic institutions and biotechnology partners to accelerate the delivery of life‐saving therapies.

Key Stats

• Today's Range: $51.50 to $51.50
• 50-Day Range: $18.50 to $50.96
• 52-Week Range: $10.14 to $56.83
• Volume: 5,268 shs
• Average Volume: 193,994 shs
• Market Capitalization: $1.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.14
• Consensus Rating: Buy

Cidara Therapeutics Stock Analysis - MarketRank™

Cidara Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 173rd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cidara Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cidara Therapeutics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cidara Therapeutics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cidara Therapeutics has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.45% of the float of Cidara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cidara Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cidara Therapeutics has recently increased by 36.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cidara Therapeutics does not currently pay a dividend.

Dividend Growth

Cidara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

8.45% of the float of Cidara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cidara Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cidara Therapeutics has recently increased by 36.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.61

News Sentiment

Cidara Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cidara Therapeutics this week, compared to 3 articles on an average week.

Search Interest

12 people have searched for CDTX on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

MarketBeat Follows

6 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,999,988.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.89% of the stock of Cidara Therapeutics is held by insiders.

Percentage Held by Institutions

Only 35.82% of the stock of Cidara Therapeutics is held by institutions.

CDTX Stock Analysis - Frequently Asked Questions

How have CDTX shares performed this year?

Cidara Therapeutics' stock was trading at $26.88 at the beginning of 2025. Since then, CDTX stock has increased by 89.3% and is now trading at $50.88.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Thursday, May, 8th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.45) by $3.79.
Read the conference call transcript.

When did Cidara Therapeutics' stock split?

Cidara Therapeutics's stock reverse split on the morning of Wednesday, April 24th 2024.The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cidara Therapeutics IPO?

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDTX
• CIK: 1610618
• Web: www.cidara.com
• Phone: (858) 752-6170
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cidara Therapeutics: $57.14
• High Price Target: $75.00
• Low Price Target: $45.00
• Potential Upside/Downside: +12.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($29.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.83 million
• Net Margins: N/A
• Pretax Margin: -61,454.97%
• Return on Equity: -73.04%
• Return on Assets: -54.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 807.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.92 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 20,160,000
• Free Float: 19,380,000
• Market Cap: $1.03 billion
• Optionable: No Data
• Beta: 1.14